Dr. Michael Blute on Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
- Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60-66.
- Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Metastatic Renal Cancer Patients Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study [published online June 20, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.66.7931.
- Joyce DD, Psutka SP, Groeschl RT, et al. Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study [published online August 17, 2016]. DOI: 10.1016/j.urology.2016.08.015.
- Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28(4):543-547.
- Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482-487.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.